Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia

Ueno, Takehisa; Takase, Koki; Toyama, Chiyoshi; Deguchi, Koichi; Masahata, Kazunori; Nomura, Motonari; Watanabe, Miho; Kamiyama, Masafumi; Tazuke, Yuko; Bessho, Kazuhiko; Okuyama, Hiroomi

doi:https://doi.org/10.1016/j.jpedsurg.2022.02.041

Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia

Ueno, Takehisa; Takase, Koki; Toyama, Chiyoshi et al.

Journal of Pediatric Surgery, 2022, 57, 1215-1220

Number of Access:1,239（2025-07-22 22:15 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/87646

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available
JPS_2022_3_56	pdf	None	363 KB	179	2023.07.01
Table1	pdf	None	367 KB	33	2023.07.01
Table2	pdf	None	384 KB	31	2023.07.01
Fig.1	jpg	None	250 KB	13	2023.07.01
Fig.2	jpg	None	260 KB	13	2023.07.01
Fig.3	jpg	None	267 KB	15	2023.07.01
Fig.4	jpg	None	291 KB	16	2023.07.01

Creative Commons : Attribution - NonCommercial - NoDerivatives

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia
Creator	NRID 1000010456957 1000010456957 ORCID 0000-0002-4639-8814 0000-0002-4639-8814 researchmap permalink ueno-pedsurg ueno-pedsurg Scopus Author ID 21743992300 21743992300 CreatorName Ueno, Takehisa
	CreatorName Takase, Koki
	NRID 1000010839369 1000010839369 CreatorName Toyama, Chiyoshi
	NRID 1000000747082 1000000747082 researchmap permalink deguchi_koichi deguchi_koichi Scopus Author ID 57139781700 57139781700 CreatorName Deguchi, Koichi
	NRID 1000040588381 1000040588381 researchmap permalink masahata masahata Scopus Author ID 22938353400 22938353400 CreatorName Masahata, Kazunori
	NRID 1000040546909 1000040546909 researchmap permalink moto_pedsurg moto_pedsurg Scopus Author ID 35208741700 35208741700 ORCID 0009-0004-0959-7461 0009-0004-0959-7461 CreatorName Nomura, Motonari
	NRID 1000040791728 1000040791728 researchmap permalink miho miho Scopus Author ID 56282966800 56282966800 ORCID 0000-0001-6691-0611 0000-0001-6691-0611 CreatorName Watanabe, Miho
	NRID 1000020403074 1000020403074 researchmap permalink kamiyamapedsurg kamiyamapedsurg Scopus Author ID 55559187300 55559187300 CreatorName Kamiyama, Masafumi
	NRID 1000010397698 1000010397698 researchmap permalink yukotazuke-osaka yukotazuke-osaka Scopus Author ID 7006109798 7006109798 ORCID 0000-0002-8335-0414 0000-0002-8335-0414 CreatorName Tazuke, Yuko
	NRID 1000080423169 1000080423169 CreatorName Bessho, Kazuhiko
	NRID 1000030252670 1000030252670 researchmap permalink okuyamahiroomi okuyamahiroomi Scopus Author ID 35496082300 35496082300 ORCID 0000-0002-1347-282X 0000-0002-1347-282X CreatorName Okuyama, Hiroomi
Subject	Liver fibrosis
	Cirrhosis
	Liver biopsy
	Liver transplantation
	Fibrosis marker
Abstract	Background: : Pediatric patients sometimes develop graft fibrosis after living donor liver transplant (LDLT). Autotaxin is a recently developed serum marker for hepatic fibrosis. We studied the relationship between serum autotaxin levels and histological findings in patients after LDLT for biliary atresia (BA). Methods: Information on patients aged <19 years who received LDLT for BA and were followed for at least 1 year after LDLT was gathered. Autotaxin levels were compared with pathological fibrosis scores. Results: The study included 52 patients, of whom 4 patients had no fibrosis (F0), 36 patients had F1 fibrosis, and 12 patients had F2. The median serum autotaxin level was 0.89 mg/L. In patients with portal vein (PV) complications such as stenosis or thrombosis (n = 7), the mean autotoxin level was 1.25 mg/L compared with 0.95 mg/L in patients without PV complications (p = 0.004). Among patients without PV complications, the mean autotaxin level was 0.90, 0.88, and 1.18 mg/L in F0, F1, and F2 fibrosis, respectively. The mean autotaxin was higher in F2 fibrosis than in F0 or F1 fibrosis (p<0.05). Autotoxin had a high area under the curve (0.86) with the cut-off level of 0.897 mg/L. Conclusion: Serum autotaxin is a novel marker for liver fibrosis in patients after pediatric LDLT for BA. Type of study: : Study of Diagnostic Test. Level of evidence: : Level II.
Publisher	Elsevier
Source Title	Journal of Pediatric Surgery
Volume (Issue)	57
Page	1215-1220
Date of Issued	2022-07
Language	English
Handle URL	https://hdl.handle.net/11094/87646
PISSN	00223468
eISSN	15315037
Relation.isVersionOf	DOI (Publisher Version) https://doi.org/10.1016/j.jpedsurg.2022.02.041
Access Rights	open access
CopyRight	© 2022. This manuscript version is made available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
oaire:version	Accepted Manuscript
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Journal of Pediatric Surgery. 2022, 57, p. 1215-1220
DC.title	Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia
DC.creator	Ueno, Takehisa
	Takase, Koki
	Toyama, Chiyoshi
	Deguchi, Koichi
	Masahata, Kazunori
	Nomura, Motonari
	Watanabe, Miho
	Kamiyama, Masafumi
	Tazuke, Yuko
	Bessho, Kazuhiko
	Okuyama, Hiroomi
DC.publisher	Elsevier
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2022-07
DC.identifier	https://doi.org/10.1016/j.jpedsurg.2022.02.041
DC.subject	Liver fibrosis
	Cirrhosis
	Liver biopsy
	Liver transplantation
	Fibrosis marker
DCTERMS.abstract	Background: : Pediatric patients sometimes develop graft fibrosis after living donor liver transplant (LDLT). Autotaxin is a recently developed serum marker for hepatic fibrosis. We studied the relationship between serum autotaxin levels and histological findings in patients after LDLT for biliary atresia (BA). Methods: Information on patients aged <19 years who received LDLT for BA and were followed for at least 1 year after LDLT was gathered. Autotaxin levels were compared with pathological fibrosis scores. Results: The study included 52 patients, of whom 4 patients had no fibrosis (F0), 36 patients had F1 fibrosis, and 12 patients had F2. The median serum autotaxin level was 0.89 mg/L. In patients with portal vein (PV) complications such as stenosis or thrombosis (n = 7), the mean autotoxin level was 1.25 mg/L compared with 0.95 mg/L in patients without PV complications (p = 0.004). Among patients without PV complications, the mean autotaxin level was 0.90, 0.88, and 1.18 mg/L in F0, F1, and F2 fibrosis, respectively. The mean autotaxin was higher in F2 fibrosis than in F0 or F1 fibrosis (p<0.05). Autotoxin had a high area under the curve (0.86) with the cut-off level of 0.897 mg/L. Conclusion: Serum autotaxin is a novel marker for liver fibrosis in patients after pediatric LDLT for BA. Type of study: : Study of Diagnostic Test. Level of evidence: : Level II.
DC.rights	© 2022. This manuscript version is made available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
DC.format	87646
citation_title	Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia
citation_author	Ueno, Takehisa
	Takase, Koki
	Toyama, Chiyoshi
	Deguchi, Koichi
	Masahata, Kazunori
	Nomura, Motonari
	Watanabe, Miho
	Kamiyama, Masafumi
	Tazuke, Yuko
	Bessho, Kazuhiko
	Okuyama, Hiroomi
citation_publisher	Elsevier
citation_language	English
citation_date	2022-07
citation_journal_title	Journal of Pediatric Surgery
citation_volume	57
citation_firstpage	1215
citation_lastpage	1220
citation_doi	https://doi.org/10.1016/j.jpedsurg.2022.02.041
citation_public_url	https://hdl.handle.net/11094/87646

Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia

Link to primary information

Item Information

Show details